AbbVie Agrees To Acquire Aliada Therapeutics For $1.4 Bln In Cash

(RTTNews) - AbbVie, Inc. (ABBV) and biotechnology company Aliada Therapeutics announced Monday a definitive agreement under which AbbVie will acquire all outstanding Aliada equity for $1.4 billion in cash, subject to certain customary adjustments.

Aliada's lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aß) antibody in development for the treatment of Alzheimer's disease.

Aliada is advancing therapeutic candidates using its Modular Delivery (MODEL) platform, engineered for high-precision CNS drug delivery.

The acquisition allows AbbVie to utilize Aliada's novel blood-brain barrier (BBB)-crossing technology to enhance discovery and development efforts across neuroscience.

The transaction is expected to close in fourth quarter of 2024, subject to regulatory approvals and other customary closing conditions.